Julian Macoveanu, Jeff Zarp Petersen, Johanna Mariegaard, Andreas Elleby Jespersen, Katrine Cramer, Caroline Fussing Bruun, Helle Østergaard Madsen, Martin Balslev Jørgensen, Maj Vinberg, Patrick M Fisher, Gitte Moos Knudsen, Ida Hageman, Hannelore Ehrenreich, Lars Vedel Kessing, Kamilla Woznica Miskowiak
BACKGROUND: Persistent cognitive impairment is frequent across bipolar disorder (BD) and major depressive disorder (MDD), highlighting an urgent need for pro-cognitive treatments. AIM: This study investigated effects of erythropoietin (EPO) on cognitive impairment and dorsal prefrontal cortex (dPFC) activity in affective disorders. METHODS: In this randomized, double-blinded, placebo-controlled trial, cognitively impaired patients with remitted BD or MDD received 1 weekly recombinant human EPO (40,000 IU/mL) or saline infusion for a 12-week period...
March 22, 2024: Journal of Psychopharmacology